| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/03/1999 | EP0899332A2 The G-protein coupled receptor HFIAO41 |
| 03/03/1999 | EP0899261A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists |
| 03/03/1999 | EP0745080B1 Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace |
| 03/03/1999 | EP0675893B1 Anticonvulsant sorbopyranose sulfamates |
| 03/03/1999 | CN1209319A Preparation method for medicinal composition containing aza-steroid compound for treating prostatic hyperplasia |
| 03/03/1999 | CA2242313A1 Signal recognition particle polypeptides and polynucleotides |
| 03/02/1999 | US5877198 Treatment of urinary incontinence |
| 03/02/1999 | US5877016 Human trk receptors and neurotrophic factor inhibitors |
| 03/02/1999 | CA2242315A1 Mecb |
| 02/28/1999 | CA2241427A1 Novel pyrr homolog |
| 02/26/1999 | CA2241431A1 Novel spoiiie |
| 02/25/1999 | WO1999009049A1 Hypoxia-regulated genes |
| 02/25/1999 | WO1999009046A1 Hypoxia-regulated genes |
| 02/25/1999 | WO1999009016A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 02/25/1999 | WO1999008684A2 Solutions containing azasteroids |
| 02/25/1999 | WO1999008682A1 A method of preventing or treating estrogen-dependent diseases and disorders |
| 02/25/1999 | WO1999008678A1 Heterocyclic vinylethers against neurological disorders |
| 02/25/1999 | WO1999008668A2 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
| 02/25/1999 | WO1999008666A2 Pharmaceutical composition comprising an azateroid |
| 02/25/1999 | WO1998053050A3 Short peptides which selectively modulate the activity of serine/threonine kinases |
| 02/25/1999 | CA2295023A1 Solutions containing azasteroids |
| 02/25/1999 | CA2295016A1 Pharmaceutical composition |
| 02/24/1999 | EP0897980A2 CXCR4B: A human splice variant of CXCR4 chemokine receptor |
| 02/24/1999 | EP0897979A2 Human sdr2 cdna clone |
| 02/24/1999 | EP0897303A1 Inhibitors of farnesyl-protein transferase |
| 02/24/1999 | EP0703904B1 Pyrimidine cyanoguanidines as k-channel blockers |
| 02/24/1999 | CN1209129A Antagonists of gonadotropin releasing hormone |
| 02/24/1999 | CN1208643A Medicine for treating prostatosis and method for preparing same |
| 02/24/1999 | CN1042226C Heterocyclic derivatives and method for preparing the salt thereof |
| 02/23/1999 | US5874245 Human G-protein coupled receptor (HIBCD07) |
| 02/20/1999 | CA2241429A1 Cxcr4b: a human splice variant of cxcr4 chemokine receptor |
| 02/19/1999 | CA2241433A1 Novel compounds |
| 02/18/1999 | WO1999007737A2 Lsr receptor, cloning and uses |
| 02/18/1999 | WO1999007736A2 Lipoprotein-regulating medicaments |
| 02/18/1999 | WO1999007703A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 02/18/1999 | WO1999007695A2 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST |
| 02/18/1999 | WO1999007681A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 02/18/1999 | WO1999007670A1 Anthranilic acid analogs |
| 02/18/1999 | WO1999007669A1 Anthranilic acid analogs |
| 02/18/1999 | WO1999007406A1 C1q AND COLLECTIN RECEPTOR |
| 02/18/1999 | WO1999007365A1 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| 02/18/1999 | WO1999007363A1 Use of the compound 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamido acetate for the production of an anti-inflammatory drug with prevention of gastric hypersecretion and renal impairment |
| 02/18/1999 | WO1999007351A2 Indole derivatives and their use as mcp-1 antagonists |
| 02/18/1999 | CA2298849A1 Lipoprotein-regulating medicaments |
| 02/18/1999 | CA2298702A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 02/18/1999 | CA2297889A1 Alpha 1a adrenergic receptor antagonist |
| 02/18/1999 | CA2297412A1 Anthranilic acid analogs |
| 02/18/1999 | CA2297409A1 Anthranilic acid analogs |
| 02/18/1999 | CA2297290A1 Chemical compounds |
| 02/18/1999 | CA2274302A1 Lsr receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications |
| 02/18/1999 | CA2245041A1 Optical active 1,4-dihydropyridine compounds as bradykinin antagonists |
| 02/17/1999 | EP0897011A2 Novel arginine deiminase |
| 02/17/1999 | EP0897008A2 His5 |
| 02/17/1999 | EP0896822A1 4-Aminopyrrole (3,2-d) pyrimidines as neuropeptide Y receptor antagonists |
| 02/17/1999 | EP0896543A1 Drug for the treatment of tumours |
| 02/17/1999 | CN1208418A Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their preparation and use |
| 02/17/1999 | CN1208417A Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| 02/17/1999 | CN1208413A Antagonists of gonadotropin releasing hormone |
| 02/17/1999 | CN1208412A Antagonists of gonadotropin releasing hormone |
| 02/17/1999 | CN1208346A Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors |
| 02/17/1999 | CN1208034A Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 02/17/1999 | CN1207919A Application of theachrome in preparing medicine for hyperuricemia |
| 02/17/1999 | CN1207916A Application of theachrome in preparing medicine for prostatauxe |
| 02/16/1999 | US5872119 2-Naphthamide derivatives and their therapeutic applications |
| 02/16/1999 | US5872107 Anticarcinogenic agents capture therapy for tumors |
| 02/15/1999 | CA2224096A1 The g-protein coupled receptor hfia041 |
| 02/13/1999 | CA2240627A1 Novel ratc |
| 02/13/1999 | CA2240623A1 Novel rata |
| 02/12/1999 | CA2239835A1 Human sdr2 cdna clone |
| 02/11/1999 | WO1999006434A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006433A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006423A1 83 human secreted proteins |
| 02/11/1999 | WO1999006409A1 Tricyclic vasopressin agonists |
| 02/11/1999 | WO1999006403A1 Tricyclic vasopressin agonists |
| 02/11/1999 | WO1999006397A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
| 02/11/1999 | WO1999006391A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof |
| 02/11/1999 | WO1999006390A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | WO1999006384A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring |
| 02/11/1999 | WO1999006383A1 Piperazine derivatives active on the lower urinary tract |
| 02/11/1999 | WO1999006382A1 1,4-disubstituted piperazines |
| 02/11/1999 | WO1999006354A1 Il-8 receptor antagonists |
| 02/11/1999 | WO1999006057A1 Soya extract, process for its preparation and pharmaceutical composition |
| 02/11/1999 | WO1999006025A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases |
| 02/11/1999 | CA2298852A1 83 human secreted proteins |
| 02/11/1999 | CA2297894A1 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
| 02/11/1999 | CA2297407A1 Tricyclic vasopressin agonists |
| 02/11/1999 | CA2297095A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring |
| 02/11/1999 | CA2294064A1 Il-8 receptor antagonists |
| 02/11/1999 | CA2290750A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2290746A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 02/11/1999 | CA2239836A1 Novel arginine deiminase |
| 02/11/1999 | CA2239813A1 Novel nrdd |
| 02/11/1999 | CA2239221A1 Novel his5 |
| 02/10/1999 | CN1207743A Inhibitors of interleukin-1 'beta' converting enzyme |
| 02/10/1999 | CN1207675A Sublingual and buccal administration of selegiline |
| 02/10/1999 | CN1207671A PGE-1 contg. lyophilized liposomes for use in treatment of erectile dysfunction |
| 02/09/1999 | US5869663 Intermediates for neurokinin receptor antagonists |
| 02/09/1999 | US5869537 Macrophage lipid chemoattractant |
| 02/09/1999 | US5869534 Administering aminoguanidine and analogs thereof to reduce lipid oxidation and inhibit an increase in serum low density lipoproteins to prevent disease states characterized by the presence of advanced glycosylation endproducts |
| 02/09/1999 | US5869531 No undesireable salidiuretic properties; treating ischemia induced disorders |